1. Corey RG, Wilcox MH, Talbot GH et al. on behalf of the CANVAS 1 investigators. CANVAS 1: the first
Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with
complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65 Suppl 4: iv41–51.
2. Wilcox MH, Corey RG, Talbot GH et al. on behalf of the CANVAS 2 investigators. CANVAS 2: the
second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of
patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65 Suppl 4:
iv53–65.
3. File TM Jr, Low DE, Eckburg PB et al. on behalf of the FOCUS 1 investigators. FOCUS 1: a randomized,
double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus
ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011; 66 Suppl 3: iii19 –32.
4. Ge Y, Biek D, Talbot G. Sahm. In vitro proling of Ceftaroline against a collection of
recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother
2008; 52:3398–407.
5. Saravolatz L, Pawlak J, Johnson L. In vitro acitivity of ceftaroline against communityassociated
methicillin-resistant, vancomycin- intermediate, vancomycin-resistant and daptomycinnonsusceptilbe
Staphylococcus aureus isolates. Antimicrob Agents Chemother 2010; 54:3027–30.
6. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility
Testing: Twenty-third Informational Supplement M100-S23. Wayne, PA: Clinical and Laboratory
Standards Institute 2013; 72-86
7. Jones RN, Mendes RE, Sader HS. Ceftaroline activity against pathogens associated with complicated skin
and skin structure infections: results from an international surveillance study. J Antimicrob Chemother
2010; 65 Suppl 4: iv17–31.
Thank you for copying data from http://www.arastirmax.com
